Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $128.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective increased by UBS Group from $90.00 to $128.00 in a research note published on Tuesday,Benzinga reports. UBS Group currently has a buy rating on the stock.

A number of other research analysts have also recently commented on KYMR. Mizuho upped their price target on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Royal Bank Of Canada reissued an “outperform” rating and issued a $108.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Guggenheim started coverage on shares of Kymera Therapeutics in a research note on Monday, November 3rd. They issued a “buy” rating and a $90.00 target price on the stock. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Bank of America boosted their price target on Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Kymera Therapeutics Stock Performance

KYMR opened at $83.52 on Tuesday. The stock’s 50 day moving average price is $78.75 and its 200-day moving average price is $66.52. Kymera Therapeutics has a one year low of $19.44 and a one year high of $103.00. The stock has a market cap of $6.82 billion, a price-to-earnings ratio of -22.70 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. Kymera Therapeutics’s revenue was down 60.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.88) EPS. As a group, analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 4,895 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $417,543.50. Following the transaction, the chief financial officer directly owned 232,588 shares in the company, valued at approximately $19,839,756.40. This trade represents a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the completion of the transaction, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at $60,130,760.70. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 561,698 shares of company stock worth $50,388,337. Insiders own 16.01% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently made changes to their positions in KYMR. PNC Financial Services Group Inc. boosted its position in Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after purchasing an additional 770 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares in the last quarter. Osaic Holdings Inc. grew its position in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares during the last quarter.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts across Q1–Q4 2026 (small EPS improvements) and reiterated a Buy with a $134 target — this reduces short‑term downside expectations and supports investor interest. HC Wainwright note
• Positive Sentiment: Recent analyst target increases and bullish notes (including UBS coverage and other upgrades) signal renewed conviction in Kymera’s pipeline and cash runway; these reports are a constructive counterbalance to selling. UBS bullish note
• Positive Sentiment: Some outlets raised Kymera price targets (example: a recent note raising a target to $100), which can attract buyers and provide technical support. Price target update
• Neutral Sentiment: Technical/context: KYMR remains above its 200‑day moving average with elevated volatility (beta ~2.2); analyst consensus targets sit well above the current price, which can amplify both rallies and pullbacks. Market data
• Neutral Sentiment: Institutional activity shows modest position changes among several managers; current flows are not large enough to decisively move the stock by themselves. Institutional holdings
• Negative Sentiment: Large insider selling: Director Bruce Booth sold 81,866 shares (~$7.38M at ~ $90), a substantial, visible transaction that can be perceived as profit‑taking and pressuring the stock. Booth Form 4
• Negative Sentiment: Multiple senior executives (CFO, COO and others) disclosed sales across March 2–4, trimming positions by a few percent each—these repeated insider sales amplify short‑term negative sentiment despite company‑level explanations (e.g., diversification or tax/liquidity needs). Insider filings
• Negative Sentiment: Recent quarterly results (Feb. 26) showed an EPS miss and steep revenue decline year‑over‑year, which remains a fundamental drag on the stock until upcoming clinical milestones or revenue inflection points arrive. Earnings report

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.